NCT06308978 - A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Biotech Hunter

Enrollment

244

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2042

Conditions

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)Idiopathic Inflammatory Myositis (IIM)Systemic Sclerosis (SSc)Systemic Lupus Erythematosus (SLE)

Interventions

DRUG

FT819

FT819 will be administered as intravenous (IV) infusion at planned dose levels.

DRUG

Fludarabine

Fludarabine will be administered as an IV infusion at planned dose levels.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered as an IV infusion at planned dose levels.

DRUG

Bendamustine

Bendamustine will be administered as an IV infusion at planned dose levels.

Trial Locations (9)

27705

RECRUITING

Duke University Health System, Durham

38103

RECRUITING

Regional One Health, Memphis

44109

RECRUITING

MetroHealth, Cleveland

55455

RECRUITING

University of Minnesota Medical School, Minneapolis

68198

RECRUITING

University of Nebraska Medical Center, Omaha

73019

RECRUITING

University of Oklahoma, Oklahoma City

90027

RECRUITING

Children's Hospital Los Angeles Division Of Rheumatology, Los Angeles

92835

RECRUITING

Providence Medical Foundation, Fullerton

92868

RECRUITING

University of California Irvine, Irvine